2014年6月6日 · Stent thrombosis, MI, and Q-wave MI were all reduced with cangrelor compared with clopidogrel. The 48-hour outcomes were consistent across multiple subgroups and …

This topic addresses the use of antiplatelet therapy in patients with acute ST-elevation myocardial infarction (STEMI) from presentation until discharge. Other relevant topics include: (See …

2025年1月19日 · Clopidogrel is an antiplatelet medication approved for managing unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation …

2018年2月8日 · We examined whether P2Y 12 inhibitor choice changed among patients with recurrent MI, stent thrombosis, and/or unplanned revascularization during the first year after …

2017年8月2日 · Clopidogrel reloading occurs most frequently in patients with acute myocardial infarction (MI) who are already taking clopidogrel, particularly for STEMI. Results from a recent …

2020年12月4日 · Aspirin is often combined with a P2Y12 receptor antagonist (clopidogrel, prasugrel, or ticagrelor) for dual antiplatelet therapy (DAPT) after PCI or ACS. 3,4 Aspirin …

2013年11月1日 · Clopidogrel and ticagrelor are recommended for conservative medical management of MI in combination with aspirin (162 to 325 mg per day) for up to 12 months. …

Clinical studies have shown that long-term DAPT with ASA and an antiplatelet such as clopidogrel, prasugrel or ticagrelor reduces the risk of death from CV causes, nonfatal MI or …

2006年2月4日 · In patients with non-ST elevation ACS and those undergoing percutaneous coronary intervention (PCI), the combination of clopidogrel and aspirin reduces the risk of …

The CURE 1 trial showed a significant improvement in the combined outcome of cardiovascular death, nonfatal MI, and stroke with the use of dual oral antiplatelet therapy (aspirin and …